| Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 20506360 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To test the hypothesis that oxidative stress is increased in patients with rheumatoid arthritis (RA) due to increased inflammation and contributes to the pathogenesis of atherosclerosis. METHODS: The independent association between urinary F₂-isoprostane excretion, a measure of oxidative stress, and RA was tested using multiple linear regression models in 169 patients with RA and 92 control subjects, frequency matched for age, race, and sex. The relationship between F₂-isoprostane excretion and coronary calcium, a marker of atherosclerosis, was examined in multivariable proportional odds logistic regression models that also assessed the interactions between oxidative stress and low-density lipoprotein and high-density lipoprotein (HDL) cholesterol. RESULTS: F₂-isoprostane excretion was significantly higher in patients with RA (median 2.75 [interquartile range (IQR) 1.60-4.06] ng/mg creatinine) than in control subjects (median 1.86 [IQR 1.25-2.62] ng/mg creatinine; adjusted P = 0.006). In patients with RA, F₂-isoprostanes were positively correlated with body mass index (P < 0.001), but not with disease activity or mediators of inflammation such as the Disease Activity Score in 28 joints or serum tumor necrosis factor α, interleukin-6, and C-reactive protein concentrations in adjusted multivariable models (P > 0.05 for all). In patients with RA, F₂-isoprostanes significantly modified the effect of HDL cholesterol on coronary calcification (P = 0.02 for interaction) after adjustment for age, sex, and race. As F₂-isoprostane levels increased, HDL lost its protective effect against coronary calcification. CONCLUSION: Oxidative stress measured as F₂-isoprostane excretion was higher in patients with RA than in control subjects. Among patients with RA, higher F₂-isoprostane excretion and HDL cholesterol concentrations interacted significantly and were positively associated with the severity of coronary calcification. |
| | |
Authors:
|
Young Hee Rho; Cecilia P Chung; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Ginger L Milne; C Michael Stein |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Arthritis care & research Volume: 62 ISSN: 2151-4658 ISO Abbreviation: Arthritis Care Res (Hoboken) Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-08 Completed Date: 2010-10-26 Revised Date: 2012-05-07 |
Medline Journal Info:
|
Nlm Unique ID: 101518086 Medline TA: Arthritis Care Res (Hoboken) Country: United States |
Other Details:
|
Languages: eng Pagination: 1473-80 Citation Subset: IM |
Affiliation:
|
Vanderbilt University, Nashville, Tennessee 37232-6602, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Arthritis, Rheumatoid / blood*, pathology, urine Biological Markers / blood, urine Calcinosis / blood*, pathology, urine Cholesterol, HDL / blood* Coronary Artery Disease / blood*, pathology, urine Cross-Sectional Studies F2-Isoprostanes / urine Female Humans Male Middle Aged Oxidative Stress / physiology* Risk Factors Severity of Illness Index* |
| Grant Support | |
ID/Acronym/Agency:
|
GM07569/GM/NIGMS NIH HHS; HL65082/HL/NHLBI NIH HHS; HL67964/HL/NHLBI NIH HHS; P60 AR056116-03/AR/NIAMS NIH HHS; P60-AR056116/AR/NIAMS NIH HHS; R01 HL065082-09/HL/NHLBI NIH HHS; R01 HL067964-04/HL/NHLBI NIH HHS; UL1-RR024975/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cholesterol, HDL; 0/F2-Isoprostanes |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Shed HER2 extracellular domain in HER2-mediated tumor growth and in Trastuzumab susceptibility.
Next Document: Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis.